FAGR Fagron SA

Disclosure of notification received from Templeton Investment Counsel, LLC

Disclosure of notification received from Templeton Investment Counsel, LLC

Regulated information

Nazareth (Belgium)/Rotterdam (The Netherlands), 20 September 2022 – 7:00 PM CET

Disclosure of notification received from Templeton Investment Counsel, LLC

Pursuant to the Belgian law of 2 May 2007 regarding the disclosure of major shareholdings in listed companies, Fagron received a notification from Templeton Investment Counsel, LLC.

Notification Templeton Investment Counsel, LLC

  • On 14 September 2022, Fagron received a notification that the shareholding of Templeton Investment Counsel, LLC had crossed the lowest disclosure threshold of 3% on 13 September 2022 as the result of the disposal of voting securities or voting rights.
  • The notification is made by a ‘person that notifies alone’.
  • On 13 September 2022, Templeton Investment Counsel, LLC held a total of 2,136,016 voting rights.
  • Based on the denominator of 72,992,654 (total number of voting rights), Templeton Investment Counsel, LLC held 2.93% of the total number of voting rights on 13 September 2022.
  • Templeton Investment Counsel, LLC is a wholly owned subsidiary of Templeton Worldwide Inc., which is a wholly owned subsidiary of Franklin Resources, Inc.
  • Templeton Investment Counsel, LLC makes use of the exemption from the obligation to aggregate its holdings, as referred to in Article 11, paragraph 2 of the Law of 2 May 2007, and Article 21 of the Royal Decree of 14 February 2008.
  • As a result of a change in the investment management agreement, Templeton Investment Counsel, LLC, no longer retains the voting authority over the shares of its client account, and this led to a reduction of the voting interest of Templeton Investment Counsel, LLC in Fagron. The client now retains the responsibility to vote the shares.
  • The notification of Templeton Investment Counsel, LLC can be viewed via this .

Further information

Karen Berg

Global Investor Relations Manager

Tel. 99

About Fagron

Fagron is a leading global company active in pharmaceutical compounding, focusing on delivering personalized medicine to hospitals, pharmacies, clinics, and patients in 35 countries around the world.

Belgian company Fagron NV has its registered office in Nazareth and is listed on Euronext Brussels and Euronext Amsterdam under the ticker symbol ‘FAGR’. Fagron’s operational activities are managed by the Dutch company Fagron BV, which is headquartered in Rotterdam.

In the event of differences between the English translation and the Dutch original of this press release, the latter prevails.

Please open the link below for the press release:



EN
20/09/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Fagron SA

 PRESS RELEASE

Fagron completes acquisition of Vepakum

Fagron completes acquisition of Vepakum Regulated information – inside informationNazareth (Belgium)/Rotterdam (The Netherlands), 3 March 2026 – 7:00AM Fagron completes acquisition of Vepakum Fagron, the leading global player in pharmaceutical compounding, announces the successful completion of its acquisition of Vepakum in Latin America. The transaction, announced in December 2025, was finalized following regulatory clearance from CADE in early February 2026. Vepakum operates two facilities in São Paulo, Brazil, and specializes in high-quality pharmaceutical packaging solutions. The ac...

 PRESS RELEASE

Fagron voltooit overname van Vepakum

Fagron voltooit overname van Vepakum Gereglementeerde informatie - voorwetenschapNazareth (België)/Rotterdam (Nederland), 3 maart 2026 – 7:00 Fagron voltooit overname van Vepakum Fagron, de toonaangevende wereldwijde speler in farmaceutische bereidingen, maakt bekend dat de overname van Vepakum in Latijns-Amerika succesvol is afgerond. De transactie, die in december 2025 werd aangekondigd, kon worden voltooid nadat CADE, de Braziliaanse mededingingsautoriteit, in februari 2026 goedkeuring verleende. Vepakum beschikt over twee productiefaciliteiten in São Paulo, Brazilië, en is gespecial...

 PRESS RELEASE

Disclosure of a transparency notification from AOC Pharma S.à r.l.

Disclosure of a transparency notification from AOC Pharma S.à r.l. Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 27 02 2026 – 6PM CET Disclosure of a transparency notification from AOC Pharma S.à r.l. Pursuant to the Belgian Act of 2 May 2007 on the disclosure of major shareholdings in listed companies, Fagron received a transparency notification from AOC Pharma S.à r.l., dated 24 February 2026. Notification from AOC Pharma S.à r.l. On 24 February 2026, Fagron received a transparency notification from AOC Pharma S.à r.l., informing the Company that its sharehold...

 PRESS RELEASE

Openbaarmaking van transparantiekennisgeving van AOC Pharma S.à r.l.

Openbaarmaking van transparantiekennisgeving van AOC Pharma S.à r.l. Gereglementeerde informatie Nazareth (België)/Rotterdam (Nederland), 27 februari 2026 – 18:00 CET Openbaarmaking van transparantiekennisgeving van AOC Pharma S.à r.l. Overeenkomstig de Belgische Wet van 2 mei 2007 op de openbaarmaking van belangrijke deelnemingen in beursgenoteerde vennootschappen, ontving Fagron een transparantiekennisgeving van AOC Pharma S.à r.l., gedateerd 24 februari 2026. Kennisgeving van AOC Pharma S.à r.l. Op 24 februari 2026 ontving Fagron een transparantiekennisgeving van AOC Pharma S.à r.l....

ING Helpdesk
  • ING Helpdesk

Benelux Morning Notes

Ackermans & van Haaren: Results capping already strong subsidiary reporting. DPS beat. Fagron: Acquisition of Pharmavit Europe, active in nutraceutical raw materials. Fugro: Patience please. Kendrion: Sees signs of improvement in EU economy. Proximus: 2026 dividend halved, 2028-30 targets a bit better on lower capex. Proximus: 4Q25 in line EBITDA on weaker sales, FCF up; 2026 guidance below on EBITDA. Recticel: Strong FY25 results, CEO transition seen as a negative

ResearchPool Subscriptions

Get the most out of your insights

Get in touch